针对乳腺癌治疗的 PI3K/Akt/mTOR 通路。
Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.
机构信息
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA.
出版信息
J Mammary Gland Biol Neoplasia. 2012 Dec;17(3-4):205-16. doi: 10.1007/s10911-012-9264-2. Epub 2012 Aug 4.
Abstract
Recent advances in genetics and genomics have revealed new pathways that are aberrantly activated in many breast cancers. Chief among these genetic changes are somatic mutations and/or gains and losses of key genes within the phosphoinositide 3-kinase (PI3K) pathway. Since breast cancer cell growth and progression is often dependent upon activation of the PI3K pathway, there has been intense research interest in finding therapeutic agents that can selectively inhibit one or more constituents of this signaling cascade. Here we review key molecules involved with aberrant PI3K pathway activation in breast cancers and current efforts to target these components for therapeutic gain.
摘要
近年来，遗传学和基因组学的进展揭示了许多乳腺癌中异常激活的新途径。这些遗传变化中主要的是磷脂酰肌醇 3-激酶（PI3K）途径中的体细胞突变和/或关键基因的增益和缺失。由于乳腺癌细胞的生长和进展通常依赖于 PI3K 途径的激活，因此人们一直致力于寻找能够选择性抑制这种信号级联反应的一个或多个组成部分的治疗剂。在这里，我们回顾了乳腺癌中异常 PI3K 途径激活所涉及的关键分子，并概述了针对这些成分进行治疗的最新研究进展。
相似文献
1
Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.针对乳腺癌治疗的 PI3K/Akt/mTOR 通路。
J Mammary Gland Biol Neoplasia. 2012 Dec;17(3-4):205-16. doi: 10.1007/s10911-012-9264-2. Epub 2012 Aug 4.
2
Targeting the PI3-kinase/Akt/mTOR signaling pathway.靶向PI3激酶/Akt/mTOR信号通路。
Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6.
3
Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.植物化学物质作为 PI3K/Akt/mTOR 抑制剂及其在乳腺癌治疗中的作用。
Recent Pat Anticancer Drug Discov. 2020;15(3):188-199. doi: 10.2174/1574892815666200910164641.
4
The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.磷脂酰肌醇-3-激酶-Akt-哺乳动物雷帕霉素靶蛋白通路作为乳腺癌的治疗靶点。
J Natl Compr Canc Netw. 2013 Jun 1;11(6):670-8. doi: 10.6004/jnccn.2013.0086.
5
Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.乳腺癌分子靶向治疗的新方法：干扰 PI3K/AKT/mTOR 信号通路。
Curr Cancer Drug Targets. 2013 Feb;13(2):188-204. doi: 10.2174/1568009611313020008.
6
Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.针对乳腺癌中的磷脂酰肌醇 3-激酶信号通路。
Oncologist. 2011;16(4):404-14. doi: 10.1634/theoncologist.2010-0402. Epub 2011 Mar 15.
7
Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.抑制组成性激活的磷酸肌醇 3-激酶/AKT 通路增强乳腺癌易感基因 1 缺陷型乳腺癌细胞中化疗药物的抗肿瘤活性。
Mol Carcinog. 2013 Sep;52(9):667-75. doi: 10.1002/mc.21905. Epub 2012 Apr 4.
8
The PI3K/AKT Pathway as a Target for Cancer Treatment.PI3K/AKT 通路作为癌症治疗的靶点。
Annu Rev Med. 2016;67:11-28. doi: 10.1146/annurev-med-062913-051343. Epub 2015 Oct 14.
9
Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.PI3K/Akt/mTOR 通路抑制剂：乳腺癌患者的新希望。
Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):29-57. doi: 10.2174/157489210789702208.
10
PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.甲状腺髓样癌中的PI3K/Akt/mTOR信号传导：一种有前景的癌症治疗分子靶点。
Endocrine. 2015 Mar;48(2):363-70. doi: 10.1007/s12020-014-0380-1. Epub 2014 Aug 13.
引用本文的文献
1
Drug resistance and tumor heterogeneity: cells and ensembles.耐药性与肿瘤异质性：细胞与细胞群体
Biophys Rev. 2025 May 31;17(3):759-779. doi: 10.1007/s12551-025-01320-y. eCollection 2025 Jun.
2
and mutations as drivers of paclitaxel resistance in breast cancer cells.以及作为乳腺癌细胞中紫杉醇耐药驱动因素的突变。
Oncol Lett. 2025 May 2;30(1):324. doi: 10.3892/ol.2025.15070. eCollection 2025 Jul.
3
Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition).PI3K/AKT/mTOR抑制剂治疗乳腺癌临床应用专家共识（2025年版）
Cancer Innov. 2025 Apr 9;4(3):e70008. doi: 10.1002/cai2.70008. eCollection 2025 Jun.
4
Phallus indusiatus Extracts Promoted MCF-7 Apoptosis Under TNFα-induced Tumor Microenvironment by Attenuating NF-kappaB and Akt Activation.竹荪提取物通过减弱核因子κB和Akt激活，在肿瘤坏死因子α诱导的肿瘤微环境下促进MCF-7细胞凋亡。
Asian Pac J Cancer Prev. 2025 Feb 1;26(2):479-487. doi: 10.31557/APJCP.2025.26.2.479.
5
PHLPP1 depletion promotes tumorigenesis and stemness in triple-negative breast cancer cells through AKT signaling.PHLPP1缺失通过AKT信号通路促进三阴性乳腺癌细胞的肿瘤发生和干性。
Med Oncol. 2025 Feb 20;42(3):80. doi: 10.1007/s12032-025-02630-7.
6
Covariate-Assisted Bayesian Graph Learning for Heterogeneous Data.用于异构数据的协变量辅助贝叶斯图学习
J Am Stat Assoc. 2024;119(547):1985-1999. doi: 10.1080/01621459.2023.2233744. Epub 2023 Sep 6.
7
Plant-Based Anticancer Compounds With a Focus on Breast Cancer.植物源抗癌化合物及其在乳腺癌中的作用
Cancer Rep (Hoboken). 2024 Oct;7(10):e70012. doi: 10.1002/cnr2.70012.
8
The Use of Patient-Derived Organoids in the Study of Molecular Metabolic Adaptation in Breast Cancer.利用患者来源的类器官研究乳腺癌中的分子代谢适应性。
Int J Mol Sci. 2024 Sep 29;25(19):10503. doi: 10.3390/ijms251910503.
9
Anticancer Drug Discovery from Natural Compounds Targeting PI3K/AKT/mTOR Signaling Pathway.基于靶向PI3K/AKT/mTOR信号通路的天然化合物的抗癌药物发现
Curr Med Chem. 2024 Oct 10. doi: 10.2174/0109298673325229240928040758.
10
A Perspective of PI3K/AKT/mTOR Pathway Inhibitors to Overcome Drug-resistance in Breast Cancer Therapy.PI3K/AKT/mTOR信号通路抑制剂克服乳腺癌治疗耐药性的研究进展
Curr Med Chem. 2025;32(10):1865-1873. doi: 10.2174/0109298673327425240815065221.
本文引用的文献
1
Synthesis and structure-activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors.合成和结构-活性关系的咪唑并[1,2-a]嘧啶-5(1H)-酮作为一个新的系列β异构体选择性的磷酸肌醇 3-激酶抑制剂。
Bioorg Med Chem Lett. 2012 Mar 15;22(6):2230-4. doi: 10.1016/j.bmcl.2012.01.092. Epub 2012 Feb 4.
2
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.BGT226 是一种口服磷脂酰肌醇-3-激酶和 mTOR 抑制剂，在晚期实体瘤患者中的 I 期安全性、药代动力学和药效学研究。
Ann Oncol. 2012 Sep;23(9):2399-2408. doi: 10.1093/annonc/mds011. Epub 2012 Feb 22.
3
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.结直肠癌对 BRAF(V600E)抑制的无应答性通过 EGFR 的反馈激活。
Nature. 2012 Jan 26;483(7387):100-3. doi: 10.1038/nature10868.
4
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.鉴定和表征 NVP-BKM120，一种口服的全类 I PI3-激酶抑制剂。
Mol Cancer Ther. 2012 Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-0474. Epub 2011 Dec 21.
5
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.依维莫司用于绝经后激素受体阳性的晚期乳腺癌。
N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.
6
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.帕妥珠单抗联合曲妥珠单抗加多西他赛治疗转移性乳腺癌。
N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.
7
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.人表皮生长因子受体 2（HER2）过表达的原发性乳腺癌转移部位 HER2 表达缺失。
J Clin Oncol. 2012 Feb 20;30(6):593-9. doi: 10.1200/JCO.2010.33.8889. Epub 2011 Nov 28.
8
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.前瞻性研究评估乳腺癌患者转移性疾病组织确认的影响。
J Clin Oncol. 2012 Feb 20;30(6):587-92. doi: 10.1200/JCO.2010.33.5232. Epub 2011 Nov 28.
9
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.磷脂酰肌醇 3-激酶通路中的突变：在乳腺癌的肿瘤进展中的作用及治疗意义。
Breast Cancer Res. 2011;13(6):224. doi: 10.1186/bcr3039. Epub 2011 Nov 1.
10
CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.CAL-101：一种用于治疗淋巴恶性肿瘤的磷脂酰肌醇-3-激酶 p110-delta 抑制剂。
Expert Opin Investig Drugs. 2012 Jan;21(1):15-22. doi: 10.1517/13543784.2012.640318. Epub 2011 Nov 24.
Zotero 插件